Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Gustav A. Christensen
AddedFeb 17, 2024
UpdatedMay 31, 2026
Gustav A. Christensen

Gustav A. Christensen

Board Member, Morphic Therapeutic

CrunchbaseLinkedIn

Gustav A. Christensen's Career

Morphic Therapeutic
Morphic Therapeutic

Waltham, MA, US

Board Member· Board
Generation Bio
Generation Bio

Cambridge, MA, US

Board Member· Board
Phylos
Phylos

Lexington, KY, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Gustav A. Christensen's Career

Morphic Therapeutic
Morphic Therapeutic
Public$510.5M1022015Waltham, MA, US
Board Member· Board

Leadership at Morphic Therapeutic

Susannah GraySusannah GrayBoard Member
Praveen TipirneniPraveen TipirneniBoard Member
Norbert BischofbergerNorbert BischofbergerBoard Member
Martin EdwardsMartin EdwardsBoard Member
Otello StampacchiaOtello StampacchiaBoard Member
Joseph P. SlatteryJoseph P. SlatteryBoard Member

Similar to Morphic Therapeutic

Pliant TherapeuticsPliant TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2015Pliant TherapeuticsSouth San Francisco, CA, US · est. 2015

Pliant Therapeutics: A California-based biopharmaceutical company innovating therapies for fibrotic diseases.

Public · $694.9M124
MorphoceuticalsMorphoceuticalsMarblehead, MA, USBiotechnologyest. 2020MorphoceuticalsMarblehead, MA, US · est. 2020

Morphoceuticals Inc.: Pioneering bioelectric solutions for limb regeneration in biotechnology.

Seed · $8M8
Forward TherapeuticsForward TherapeuticsPalm Beach Gardens, FL, USOral Therapiesest. 2022Forward TherapeuticsPalm Beach Gardens, FL, US · est. 2022

Forward Therapeutics: Innovating chronic inflammatory treatment through advanced oral immune therapies.

Series A · $50M2
VeraMorphVeraMorphMansfield, MA, USPharmaceuticalsest. 2017VeraMorphMansfield, MA, US · est. 2017

VeraMorph: Innovating polymer-based oral dosage technology in pharmaceuticals since 2017.

Angel · $225k2
Generation Bio
Generation Bio
Public$536.4M1502016Cambridge, MA, US
Board Member· Board

Recent news

Vocal Image is using AI to help people communicate betterTechCrunch · 2025

Leadership at Generation Bio

Donald NicholsonDonald NicholsonBoard Member
Catherine Stehman-BreenCatherine Stehman-BreenBoard Member
Andrew ScharenbergAndrew ScharenbergBoard Member
Ron CooperRon CooperBoard Member
Mark D. AngelinoMark D. AngelinoCo-Founder
Charles RowlandCharles RowlandBoard Member
Phylos
Phylos
Series B$25M6Lexington, KY, US
CEO· C-Suite · Management

Leadership at Phylos

Jeff BirdJeff BirdBoard Member

Gustav A. Christensen's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Gustav A. Christensen

Jessica GreenJessica GreenCEO · PhylagenRob RichardsRob RichardsFounder · BiophyxJohn LibsJohn LibsFounder · Phyllom BioProductsJames EvansJames EvansFounder & CEO · PhenoVista BiosciencesRyan ShepherdRyan ShepherdCEO · PhylloTechVenkat KrishnanVenkat KrishnanCEO · Bionpharma